💨 Abstract

States are struggling with the rising costs of popular GLP-1 drugs like Wegovy, Ozempic, and Zepbound, particularly for Medicaid patients. Some states are considering restricting access to these drugs for weight loss, requiring patients to meet certain body-mass index criteria or try less expensive treatments first. This is due to the high cost, with the annual cost per patient averaging $12,000, and the increasing number of prescriptions.

Courtesy: wtop.com

Summarized by Einstein Beta 🤖